Back to News
Market Impact: 0.1
Eli Lilly To Showcase Retatrutide, Foundayo & EloraTZP Data At EASD 2026
Source: Nasdaq
Healthcare & Biotech
Eli Lilly announced it will present new data from its cardiometabolic portfolio at the European Association for the Study of Diabetes annual meeting in Milan from September 28 to October 2, 2026. The announcement provides no clinical results, product-specific updates, or financial guidance.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.05
Ticker Sentiment
LLY0.20
More News
- Wells Fargo sees improvement in a key metric — plus, Lilly gets praise beyond GLP-1s
- Mounjaro's maker has more room to run amid GLP-1 boom, Berenberg says
- Lilly to present cardiometabolic drug data at EASD conference
- Berenberg upgrades Eli Lilly stock rating on obesity drug strength
- Jim Cramer's top 10 things to watch in the stock market Tuesday
- Beta Bionics prices $150M public offering at $17.25/share